Literature DB >> 8698343

Phenotypic variability in two families with novel splice-site and frameshift NF2 mutations.

V F Mautner1, M E Baser, L Kluwe.   

Abstract

Neurofibromatosis 2 (NF2) is a clinically variable autosomal dominant disorder, caused by mutations in the NF2 tumor suppressor gene on chromosome 22q12, that predisposes to nervous system tumors and ocular abnormalities. To assess intrafamilial phenotypic variability, we performed mutation analysis and clinical assessment on two multigeneration NF2 families with five patients and seven asymptomatic first-degree relatives of patients. One family had a point mutation of agCC --> ggCC at position 1447-2 at the exon 13/14 boundary predicted to lead to an altered splice acceptor sequence and exon deletion. The other family had an insertion of 2 base pairs (TC) at position 761 in exon 8, leading to a frameshift. Both mild and severe phenotypes occurred in each family, indicating that phenotypic variability in NF2 can be caused by factors other than NF2 mutations. Genetic counseling of NF2 families should include the possibility that presymptomatic NF2 mutation carriers can develop a different phenotype than previously diagnosed patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8698343     DOI: 10.1007/s004390050191

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  4 in total

1.  Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study.

Authors:  Michael E Baser; Lisa Kuramoto; Harry Joe; J M Friedman; Andrew J Wallace; James E Gillespie; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2004-06-09       Impact factor: 11.025

2.  The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.

Authors:  J Jason Clark; Matthew Provenzano; Henry R Diggelmann; Ningyong Xu; Skylar S Hansen; Marlan R Hansen
Journal:  Otol Neurotol       Date:  2008-09       Impact factor: 2.311

3.  Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution.

Authors:  Claire Forde; Andrew T King; Scott A Rutherford; Charlotte Hammerbeck-Ward; Simon K Lloyd; Simon R Freeman; Omar N Pathmanaban; Emma Stapleton; Owen M Thomas; Roger D Laitt; Stavros Stivaros; John-Paul Kilday; Grace Vassallo; Catherine McBain; Simon Kerrigan; Miriam J Smith; Martin G McCabe; Elaine F Harkness; D Gareth Evans
Journal:  Neuro Oncol       Date:  2021-07-01       Impact factor: 12.300

4.  The molecular biology of vestibular schwannomas and its association with hearing loss: a review.

Authors:  Erika Celis-Aguilar; Luis Lassaletta; Miguel Torres-Martín; F Yuri Rodrigues; Manuel Nistal; Javier S Castresana; Javier Gavilan; Juan A Rey
Journal:  Genet Res Int       Date:  2012-02-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.